Amgen has filed an application for approval of its biosimilar to AbbVie's top-selling Humira.
Early human clinical trial results suggest that a better drug for lowering bad cholesterol may be on the horizon.
New drug launches are beginning to dent demand for the company's top selling medication.
Looking to add a few stocks to your portfolio that offer a healthy margin of safety? Here are a few names to consider.
Four new late-stage studies from Gilead Sciences demonstrate that it's once again raised the bar in treating hepatitis C. Can anything stop Gilead?
Companies are rolling out cardiovascular drugs in a bid to tap into a massive and growing market, but not every one of these companies belongs in investor portfolios.
As the first generation of the cholesterol-lowering drugs hits the market, investors should already be looking at the next-generation products.
Agenus Inc., Array BioPharma, and Idera Pharmaceuticals are expecting to release data from cancer drug trials in the coming year.
Advaxis and Agenus have been two of the best performing stocks of 2015. Can they continue to crush the broader markets or is it time to take profits?
One Foolish investor shines a bright light on his biotech stocks predictions for this year.